Mission Bio has recently announced the launch of the very first and possibly the sole platform capable of sequencing protein and DBA in a single cell to more accurately spot cancer targets. This innovation is touted as a major breakthrough in precision medicine.
The company has revealed that the single-cell-multi-omic platform, known as Tapestri Platform will offer insights necessary to boost the development of impactful and innovative cancer therapies. According to reports, this is a first-of-its-kind technology, with regards to accurate detection of protein changes and DNA simultaneously in a same cell. This is major capability that can help healthcare providers offer more impactful precision therapies.
As per sources, a meagre 3% of cancer drugs tested between 2000 and 2015 in clinical trial are approved for use in treatment of patients. Even among this, not all biomarkers such as DNA mutation are effective in every patient. This causes a high rate and increases the risk of cancer relapse.
Research organizations and research institutes around the world are looking for dynamic solutions for cancer treatment and to confront the ailment more accurately than before. The demand for more profound insights into each and every component that drives the disease is therefore crucial.
The capabilities launches in the last few days are likely to give impetus to the market for Tapestri Platform applications. The company is stoked and reveals that they aim at providing in-depth insights into the factors driving the disease so the pace of cures can be accelerated.
Such discoveries are likely to bolster cancer treatment in the future. Furthermore, the market for cancer treatment is likely to gain pace as leading players focus on finding effective cancer cure. This, coupled with government support and increasing investment in research and development are likely to boost cancer treatment discoveries in the future.
A self-described Finance Market Master, Abby James is associate Administrator who is committed to stock exchange techniques and increase financial wealth. She has spent the last 12 years making market trends and is currently most passionate about the work she is doing to cut back capital risk. Before starting a writing business, abby spent 6 years as a Bank Teller and Virtual Assistant for financial companies in the U.S. and U.K. As associates to Author turned Administrator, Abby has developed a unique perspective when it comes to failure makes success. She aspires to support stakeholders from her blogs in the next stage of her career.
Contact Me:- firstname.lastname@example.org